Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

BMI-Associated Anti-Apolipoprotein A-1 Positivity in Healthy Adults after mRNA-Vaccination against COVID-19

R. Máčalík, M. Petráš, AM. Čelko, P. Chmátal, J. Tlapák, P. Dlouhý, J. Malinová, IK. Lesná

. 2023 ; 11 (3) : . [pub] 20230316

Status neindexováno Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23002673

Elevated anti-apolipoprotein A-1 (AAA1) antibody levels associated with cardiovascular risk have been observed in previously SARS-CoV-2-infected or COVID-19-vaccinated individuals. Since patient safety is generally a priority in vaccination, we sought to investigate AAA1 antibody levels in healthy adults after mRNA vaccination. We conducted a prospective cohort study in healthy adult volunteers recruited from military workers of the Transport Air Base in Prague who had received two doses of mRNA vaccines. Anti-apolipoprotein A-1 antibody levels were determined using ELISA from serum samples obtained at three and four time points after the first and second vaccine doses, respectively, within almost 17 weeks of follow-up. The transient AAA1 positivity rate achieved 24.1% (95% confidence interval CI: 15.4-34.7%), i.e., 20 out of 83 participants had at least one positive post-vaccination sample, with a repeat positivity confirmed in only 5 of them. This rate was associated with a BMI > 26 kg/m2, as documented by an adjusted odds ratio of 6.79 (95% CI: 1.53-30.01). In addition, the highest positivity rate of 46.7% (21.3-73.4%) was observed in obese subjects with >30 kg/m2. Since the incidence rate of AAA1 positivity remained unchanged after the first and second vaccine doses, any relationship between AAA1 positivity and mRNA vaccination was inconclusive. The present study showed a transient AAA1 positivity rate associated with overweight or obesity without a proven association with mRNA vaccination.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23002673
003      
CZ-PrNML
005      
20230421100126.0
007      
ta
008      
230413s2023 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/vaccines11030670 $2 doi
035    __
$a (PubMed)36992254
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Máčalík, Roman $u Third Faculty of Medicine, Charles University, 100 00 Prague, Czech Republic $1 https://orcid.org/0000000221669403
245    10
$a BMI-Associated Anti-Apolipoprotein A-1 Positivity in Healthy Adults after mRNA-Vaccination against COVID-19 / $c R. Máčalík, M. Petráš, AM. Čelko, P. Chmátal, J. Tlapák, P. Dlouhý, J. Malinová, IK. Lesná
520    9_
$a Elevated anti-apolipoprotein A-1 (AAA1) antibody levels associated with cardiovascular risk have been observed in previously SARS-CoV-2-infected or COVID-19-vaccinated individuals. Since patient safety is generally a priority in vaccination, we sought to investigate AAA1 antibody levels in healthy adults after mRNA vaccination. We conducted a prospective cohort study in healthy adult volunteers recruited from military workers of the Transport Air Base in Prague who had received two doses of mRNA vaccines. Anti-apolipoprotein A-1 antibody levels were determined using ELISA from serum samples obtained at three and four time points after the first and second vaccine doses, respectively, within almost 17 weeks of follow-up. The transient AAA1 positivity rate achieved 24.1% (95% confidence interval CI: 15.4-34.7%), i.e., 20 out of 83 participants had at least one positive post-vaccination sample, with a repeat positivity confirmed in only 5 of them. This rate was associated with a BMI > 26 kg/m2, as documented by an adjusted odds ratio of 6.79 (95% CI: 1.53-30.01). In addition, the highest positivity rate of 46.7% (21.3-73.4%) was observed in obese subjects with >30 kg/m2. Since the incidence rate of AAA1 positivity remained unchanged after the first and second vaccine doses, any relationship between AAA1 positivity and mRNA vaccination was inconclusive. The present study showed a transient AAA1 positivity rate associated with overweight or obesity without a proven association with mRNA vaccination.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Petráš, Marek $u Third Faculty of Medicine, Charles University, 100 00 Prague, Czech Republic $1 https://orcid.org/0000000329131736
700    1_
$a Čelko, Alexander M $u Third Faculty of Medicine, Charles University, 100 00 Prague, Czech Republic $1 https://orcid.org/000000029031055X
700    1_
$a Chmátal, Petr $u Institute of Aviation Medicine, 160 00 Prague, Czech Republic
700    1_
$a Tlapák, Jakub $u Institute of Aviation Medicine, 160 00 Prague, Czech Republic $1 https://orcid.org/0000000277067647
700    1_
$a Dlouhý, Pavel $u Third Faculty of Medicine, Charles University, 100 00 Prague, Czech Republic
700    1_
$a Malinová, Jana $u Královské Vinohrady University Hospital, 100 34 Prague, Czech Republic
700    1_
$a Lesná, Ivana Králová $u Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic $u First Faculty of Medicine, Charles University and Military University Hospital, 121 08 Prague, Czech Republic $1 https://orcid.org/0000000290534123 $7 xx0112415
773    0_
$w MED00200686 $t Vaccines $x 2076-393X $g Roč. 11, č. 3 (2023)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36992254 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230413 $b ABA008
991    __
$a 20230421100119 $b ABA008
999    __
$a ok $b bmc $g 1922626 $s 1188880
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 11 $c 3 $e 20230316 $i 2076-393X $m Vaccines $n Vaccines (Basel) $x MED00200686
LZP    __
$a Pubmed-20230413

Najít záznam

Citační ukazatele

Možnosti archivace